Noopept for Health & Longevity

Evidence Review created on 09/04/2026 using AI4L / Opus 5

Also known as: Omberacetam, GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester

Motivation

Noopept (omberacetam) is a small synthetic molecule built from two amino acids, developed in Russia in the 1990s as a far more potent successor to an older memory drug. It is taken by mouth in milligram doses, reaches the brain quickly, and is converted there into a peptide the brain already makes on its own. That combination of tiny doses, rapid brain entry, and a homegrown active form is why it draws interest from people trying to sharpen memory and attention.

In Russia and several neighboring countries it is a registered prescription medicine for memory and attention problems following head injury or reduced blood flow to the brain. Elsewhere it has no approval and circulates instead as a bulk powder or capsule sold online, outside any medicines regulator’s oversight. Nearly all of the research behind it comes from the single institute that created it.

This review examines what the human and laboratory evidence shows about Noopept: how it is thought to work, what effects have been measured, what harms have been recorded, how it is dosed and monitored, and how strong or weak the underlying evidence base is.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Omberacetam

Covers the compound under its international nonproprietary name, consolidating its chemistry, Russian regulatory history, mechanism claims and Western enforcement record into a single referenced article.

Examine

N-Phenylacetyl-L-prolylglycine ethyl ester

Gives an independently graded summary of benefits, drawbacks and dosing, and states plainly that the single supportive human trial has not been replicated by any outside group.

ConsumerLab

What is Noopept? Can it really improve memory and cognition, and is it safe?

Summarizes both human trials with their response rates and dropouts, reproduces the Russian manufacturer’s contraindications, and sets out the United States legal position and typical retail pricing.

Systematic Reviews

No systematic reviews or meta-analyses for Noopept were found on PubMed as of September 4, 2026.

Noopept involves a trade-off between claimed cognitive gain and a documented rise in blood pressure, and both sides of that trade-off are unrepresented: the literature contains no systematic review or meta-analysis of its cognitive effect and none of its cardiovascular or other safety outcomes.

Mechanism of Action

Noopept is a prodrug: the body converts it into the active agent. Taken by mouth it is rapidly split by esterases and peptidases (enzymes that cut ester and peptide bonds), so the parent is barely detectable in blood while its main metabolite, cycloprolylglycine, builds up in brain tissue and is identical to a peptide the brain already produces (Gudasheva et al. 1997).

Four actions follow. It raises nerve growth factor and brain-derived neurotrophic factor (proteins that keep neurons alive and growing) in rat hippocampus (Ostrovskaya et al. 2008). It selectively increases hypoxia-inducible factor 1 (a master switch turning on genes that help cells survive low oxygen) by binding prolyl hydroxylase 2, the enzyme that tags it for destruction, leaving eight others untouched (Vakhitova et al. 2016). It enhances signaling at α7 nicotinic acetylcholine receptors (docking sites for the memory messenger acetylcholine) on hippocampal interneurons (Kondratenko et al. 2022). And it limits calcium overload and reactive oxygen species (unstable molecules that damage cells) in stressed neurons (Ostrovskaya et al. 2014).

Two accounts compete: the developing institute places hypoxia-inducible factor 1 first, others neurotrophin induction. The two have never been separated experimentally.

Key pharmacological properties: plasma half-life is under 30 minutes; oral bioavailability roughly 10%; clearance is by esterase and peptidase hydrolysis rather than by cytochrome P450 enzymes (the liver’s main drug-metabolizing family); distribution favors brain and liver; elimination is slowest in humans, with wide individual variation and no metabolites detectable in human plasma (Boyko et al. 2004).

Historical Context & Evolution

Nootropic pharmacology (drugs meant to enhance memory and thinking) began with piracetam, synthesized in Belgium in 1964 and used clinically for myoclonus (involuntary muscle jerking) and for cognitive complaints after stroke. Its intended use was treating injury, not enhancing healthy function.

From the 1980s the V. V. Zakusov Research Institute of Pharmacology in Moscow pursued a specific design principle: that the active part of a regulatory peptide is a two-amino-acid fragment at the turn of the peptide chain, so a drug can be shrunk to a dipeptide that mimics it. Applied to piracetam, this produced N-phenylacetyl-L-prolylglycine ethyl ester in 1996, coded GVS-111 and later named Noopept (Gudasheva et al. 2018). The reported findings were that it acted at roughly one-thousandth of piracetam’s dose and, unlike piracetam, affected memory consolidation and retrieval rather than acquisition alone.

Russian regulators registered it as a prescription medicine in the mid-2000s for cognitive and asthenic (persistent weakness and exhaustion) disorders after head trauma or cerebrovascular disease (disease of the brain’s blood vessels). It moved into health optimization because of milligram dosing, oral activity and an extensive animal neuroprotection literature.

Scientific opinion outside Russia did not reverse so much as never form. The trials appeared in Russian-language journals, were unblinded and were not repeated independently, so Western regulators classified the compound as an unapproved new drug rather than weighing its claims. What changed was supply, not evidence: from around 2010 bulk powder reached Western consumers, prompting enforcement action and laboratory surveillance (Cohen et al. 2021).

Expected Benefits

High 🟩 🟩 🟩

Cognitive Performance in Mild Cognitive Impairment

Noopept improves scores on cognitive and mood measures in people whose cognition is impaired by cerebrovascular disease or head trauma. The proposed basis is neurotrophin induction and better tolerance of low oxygen. Two clinical trials support it: a 56-day comparison against piracetam in 53 patients over 50 (Neznamov & Teleshova 2009), and a controlled open study in 60 stroke survivors (Amelin et al. 2011). Both were unblinded, placebo-free and run by groups tied to the developer; neither has been replicated independently, and no trial has tested unimpaired adults.

Magnitude: In the comparator trial, significant improvement was reached by 70% of Noopept-treated patients with post-concussive syndrome versus 16.7% on piracetam, and by 42.9% versus 25% among those with emotional dysregulation; the stroke trial reported significant gains at two months without publishing a between-group figure.

Medium 🟩 🟩

Reduction of Asthenic and Anxiety Symptoms

Separately from memory, Noopept is reported to reduce fatigue, exhaustion and anxiety. The proposed mechanism is cycloprolylglycine acting on stress-response circuits. Evidence comes from two separate Russian groups: a comparative trial in neurasthenia (persistent exhaustion and irritability after prolonged strain) (Chutko et al. 2008) and an electroencephalography (recording of the brain’s electrical rhythms) study in a separate cohort with post-traumatic or vascular brain injury, finding alpha and beta rhythm shifts characteristic of a nonspecific activating, anxiety-reducing agent (Bochkarev et al. 2008). Both were unblinded and Russian only.

Magnitude: Direction is consistent — symptom scores fall and brain rhythms shift toward activation — and holds in patients with diagnosed asthenic syndromes rather than healthy adults; these reports publish no effect size or between-group difference.

Reduced Neurotoxicity of Concurrent Drug Therapy

Noopept appears to blunt nervous-system and cardiac side effects caused by other medicines taken at the same time. The proposed mechanism is antioxidant and autonomic stabilization. A single controlled trial in 60 patients with newly diagnosed respiratory tuberculosis gave 10 mg twice daily for one month alongside standard antitubercular therapy, and reported normalized autonomic (automatic nervous system) and antioxidant function, less anxiety, and fewer nerve and heart adverse reactions than in the untreated comparison group (Mordyk et al. 2009). The trial was unblinded and has not been repeated.

Magnitude: Direction is a reduction in the frequency of drug-induced nervous-system and cardiac adverse reactions, holding only where a known neurotoxic drug regimen is being taken concurrently; the report gives no incidence figures for either group.

Tolerance of Heat, Cold and Low-Oxygen Exposure

This is the only benefit measured in healthy adults. In a controlled clinical trial, volunteers aged 20 to 24 were exposed in a climate chamber to cooling, heating and reduced-oxygen conditions. Noopept improved the psychological component of functional state under both cold and heat, and additionally raised physical work capacity in the heat, whereas the comparator peptides acted only under some conditions (Shabanov et al. 2007). The result is consistent with the hypoxia-inducible factor 1 mechanism but rests on one small unreplicated study.

Magnitude: Direction is improved self-rated functional state under thermal stress and increased physical work output in heat, holding during acute environmental challenge rather than at rest; the report publishes no effect size.

Low 🟩

Occupational Performance in Older Working Adults

In older teachers, two weeks of Noopept plus head and neck self-massage improved functional state and professional performance more than the drug alone (Lysenko et al. 2018). The design cannot separate drug from massage, and no untreated group existed.

Magnitude: Direction is improved occupational performance while the combined course is running and for one to two months afterward, holding only for the drug-plus-massage combination; the report publishes no outcome figure for the drug alone.

Speculative 🟨

Neurotrophin Induction ⚠️ Conflicted

A single dose lowered nerve growth factor and brain-derived neurotrophic factor expression in rat cortex but raised both in hippocampus; chronic dosing raised both (Ostrovskaya et al. 2008). Rodent only. Net: region- and schedule-dependent.

Basis is animal and cell culture only. Noopept reduced tau protein damage and cell death in amyloid-exposed nerve cells (Ostrovskaya et al. 2014) and restored memory in amyloid-injected rats (Ostrovskaya et al. 2008).

Blood Sugar and Gut-Hormone Effects

Noopept normalized glucagon-like peptide 1 (a gut hormone that triggers insulin release) and insulin in diabetic rats without inhibiting its degrading enzyme (Ostrovskaya et al. 2014). Rodent data only; no human measurement exists.

Benefit-Modifying Factors

Enzyme and transporter genotype: Noopept is cleared by esterases and peptidases rather than cytochrome P450 enzymes, so common drug-metabolism variants are unlikely to matter. No pharmacogenetic study of Noopept response has been published in any population.
Catechol-O-methyltransferase and apolipoprotein E variants: Catechol-O-methyltransferase clears dopamine from the prefrontal cortex and apolipoprotein E4 raises Alzheimer’s disease risk; both plausibly shape response to cognitive enhancers, but neither has been tested with Noopept.
Baseline cognitive and biomarker status: Every trial reporting a cognitive gain enrolled people with measurable impairment. The lower the starting score on a validated cognitive test, the larger the reported gain; no cognitive gain has been demonstrated in adults scoring in the normal range.
Sex: No human trial has reported results separately by sex. In rats given Noopept in early life, the learning effect differed between males and females (Trofimov et al. 2005), so a sex difference is biologically plausible but untested in people.
Pre-existing conditions: Benefit was demonstrated only in cerebrovascular disease, post-concussive syndrome and asthenic syndromes. Concurrent hypertension is a limiting factor, since the same trials recorded blood-pressure rises severe enough to end treatment.
Age: Trial participants were aged 50 and over, or 20 to 24 in the healthy-volunteer study. Nothing is published on adults in the intervening decades, which is exactly where most of this review’s audience sits.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: every adverse outcome recorded in people comes either from a single unblinded trial or from uncontrolled product-testing surveys, and no adverse event has been documented in more than one controlled trial.

Medium 🟥 🟥

Rise in Blood Pressure

The most consistently recorded harm. The presumed mechanism is nonspecific sympathetic (fight-or-flight) activation, matching the brain-rhythm activation pattern seen with the drug. In the 56-day comparator trial, two participants withdrew after systolic pressure rose enough to require treatment (Neznamov & Teleshova 2009). The Russian manufacturer’s package insert warns that Noopept can provoke a severe pressure rise in people who are already hypertensive and advises against combining it with blood-pressure-lowering medicines. Reversible on stopping.

Magnitude: Two of the Noopept-treated patients in the 56-day comparator trial had systolic pressure rise far enough to require treatment and to end their participation; the report publishes no incidence figure for milder elevations.

Sleep Disturbance and Irritability

Disrupted sleep and increased irritability were the other adverse effects recorded in the same 56-day trial, again consistent with a nonspecific activating action rather than a targeted one (Neznamov & Teleshova 2009). Both are dose- and timing-related in practice, and both resolve on discontinuation. Severity was mild enough that neither ended treatment, but for an audience that treats sleep as a foundational health input, the trade-off against a modest cognitive gain is unfavorable.

Magnitude: Direction is more disturbed sleep and more irritability over 56 days at 20 mg daily, holding at the full clinical dose and mild enough that neither ended treatment; the report publishes no incidence figure for either effect.

Low 🟥

Adulteration and Inaccurate Dosing of Retail Product

With no Western regulator overseeing supply, the product consumed is often not the product on the label. Analysis of ten retail cognitive supplements found omberacetam alongside undeclared phenibut, vinpocetine and picamilon (Cohen et al. 2021). European and Australian control laboratories intercepted Noopept as bulk material (Vanhee et al. 2025).

Magnitude: A single serving delivered up to 40.6 mg of omberacetam against a typical pharmacologic dose of 10 mg, a four-fold overdose, and 9 of 12 declared quantities across the tested products were inaccurate.

Hypersensitivity Reactions

The Russian manufacturer’s package insert lists allergic reactions as a recognized post-marketing adverse effect, without characterizing severity. Undeclared additions to retail product widen the possible triggers beyond the molecule itself (Cohen et al. 2021). The lactose-containing tablet is separately contraindicated in lactase deficiency (inability to digest milk sugar).

Magnitude: Not quantified in available studies. No controlled trial has measured allergic-reaction incidence; the signal rests entirely on uncounted spontaneous post-marketing reports collected by a single national marketing authorization holder.

Speculative 🟨

Headache, Dizziness and Gastrointestinal Discomfort

No controlled trial has recorded these. The basis is uncounted user reports collated by consumer reference sources, which describe them as not well established, and they remain the commonest complaints in unregulated use.

Increased Bleeding Tendency

Noopept and its metabolite showed anticoagulant and clot-dissolving activity in rodents and in laboratory assays (Ostrovskaya et al. 2002). Basis is animal and laboratory only; no human bleeding event has been reported.

Immune Modulation of Uncertain Direction ⚠️ Conflicted

Rodent work reports immune stimulation and increased spleen-cell proliferation (Kovalenko et al. 2007), while other work reports the opposite anti-inflammatory effect (Kovalenko et al. 2002). Animal basis only. Net: direction in humans is unknown.

Learning Deficits after Early-Life Exposure

Rats given Noopept on postnatal days 8–20 showed disturbed learning as adults, with fewer males succeeding (Trofimov et al. 2005). Basis is one rodent study; it underpins the manufacturer’s exclusion of minors.

Risk-Modifying Factors

Baseline blood pressure: The single most important modifier. People starting from an already elevated pressure are the group the manufacturer explicitly warns against, and the trial withdrawals for pressure rise occurred in an older cohort with cerebrovascular disease.
Enzyme and transporter genotype: Clearance runs through esterases and peptidases, not the cytochrome P450 system, so no polymorphism is known to alter exposure. No pharmacogenetic study exists, so this is an untested assumption rather than a finding.
Bleeding-related biomarkers: Platelet count and clotting time plausibly modify the theoretical bleeding risk implied by the animal anticoagulant data, though no human study has measured either during Noopept use.
Sex: No human safety data are reported separately by sex. The one animal study that examined sex found the adverse learning effect of early-life exposure fell mainly on males (Trofimov et al. 2005).
Pre-existing conditions: The manufacturer contraindicates kidney disease, liver disease, pregnancy and lactation. Uncontrolled hypertension, bleeding disorders and lactase deficiency each amplify a specific listed risk.
Age: Under 18 is a manufacturer contraindication, supported by the rodent developmental data. At the older end, coexisting hypertension and antiplatelet or anticoagulant use make both the pressure and the bleeding concern more consequential.

Key Interactions & Contraindications

Blood-pressure-lowering medicines: Caution; the manufacturer advises against combining Noopept with antihypertensives (amlodipine, lisinopril, losartan). Consequence is loss of blood-pressure control. Mitigation is weekly home monitoring, with any dose change separated from a Noopept course.
Stimulant medicines: Caution; the manufacturer advises against combining Noopept with drugs having a stimulating effect (methylphenidate, amphetamine salts, modafinil). Consequence is additive insomnia, irritability and pressure rise. Mitigation is no co-administration, with Noopept dosed before noon.
Anticoagulants and antiplatelet drugs: Caution based on animal data only (warfarin, apixaban, rivaroxaban, clopidogrel). Consequence would be increased bleeding risk. Mitigation is clotting time checked before and after starting, and Noopept stopped seven days before any procedure.
Anticonvulsants: Monitor; chronic Noopept potentiated the anticonvulsant effect of valproate in mice (Kravchenko et al. 2009). Consequence is unpredictable seizure-threshold change. Mitigation is anticonvulsant blood levels checked if a course is started.
Statins (cholesterol-lowering drugs) and other transporter substrates: No action needed. Omberacetam altered organic anion transporting polypeptides 1B1 and 1B3 (liver proteins that pull drugs from blood) and reduced atorvastatin uptake in cultured cells, but the authors judged the effect clinically insignificant (Erokhina et al. 2023).
Over-the-counter analgesics: Caution; nonsteroidal anti-inflammatory drugs (common pain relievers such as aspirin, ibuprofen and naproxen) add to the theoretical antiplatelet effect. Consequence is bruising or gastrointestinal bleeding. Mitigation is acetaminophen in their place during a course.
Over-the-counter decongestants and caffeine products: Caution; pseudoephedrine, phenylephrine and high-dose caffeine tablets add to the pressure and insomnia signal. Consequence is hypertension and disrupted sleep. Mitigation is avoidance of both after midday and a cap on total daily caffeine.
Supplements with additive blood-pressure effects: Caution; licorice root, yohimbine and high-dose synephrine each raise blood pressure independently. Consequence is compounded hypertension. Mitigation is removal for the duration of any Noopept course rather than dose adjustment.
Supplements with additive bleeding effects: Caution; fish oil above 3 g daily, Ginkgo biloba, nattokinase and high-dose vitamin E all reduce clotting. Consequence is additive bleeding tendency. Mitigation is complete separation from a Noopept course.
Other cognitive-enhancing compounds: Caution; other racetams and choline donors (alpha-GPC, citicoline) act on overlapping cholinergic pathways. Consequence is headache and overstimulation, and combined products often contain undeclared additions. Mitigation is one compound at a time.
Alcohol: Absolute avoidance per the manufacturer’s insert. Consequence is unpredictable central nervous system depression layered on an activating agent, plus added hepatic load. Mitigation is abstinence for the whole course rather than dose spacing.

Populations who should avoid Noopept:

Anyone under 18 years of age, per the manufacturer’s contraindication and the rodent developmental findings
Women who are pregnant or lactating
People with uncontrolled hypertension, taken as a resting pressure at or above 160/100 mmHg, or anyone whose pressure is not controlled on current therapy
People with hepatic impairment, in particular Child-Pugh Class B or C
People with renal impairment, taken as an estimated glomerular filtration rate below 60 mL/min/1.73 m²
People with lactase deficiency, lactose intolerance or glucose-galactose malabsorption (an inherited inability to absorb these two sugars), if using the lactose-containing tablet
People on therapeutic anticoagulation, or with a platelet count below 100 × 10⁹/L, or within 7 days of a planned surgical procedure
People with an active seizure disorder managed on valproate, unless anticonvulsant levels are being monitored

Risk Mitigation Strategies

Batch-specific certificate of analysis before first use: A third-party certificate confirming identity and content within 10% of label addresses the four-fold overdoses and undeclared phenibut found in retail supplements (Cohen et al. 2021).
Home blood-pressure baseline: Seated morning and evening readings across 14 days before starting, then weekly during use, detect the pressure rise that forced two withdrawals in the only comparator trial (Neznamov & Teleshova 2009).
Low starting dose with slow titration: 10 mg once daily for one week, then 10 mg twice daily and no higher than 30 mg daily. Gradual escalation limits the irritability and pressure elevation seen at full dose.
All dosing before 14:00: A second dose at midday rather than evening targets the sleep disturbance recorded among treated patients in the only comparator trial (Neznamov & Teleshova 2009).
Courses capped at 8 weeks with a 4-week washout: The longest trial with reported outcomes ran 56 days, so exposure beyond that is unstudied. Time limiting also forecloses indefinite use in the absence of long-term safety data.
Discontinuation 7 days before any procedure: Stopping ahead of surgery, dental extraction or colonoscopy, with no concurrent anticoagulants, addresses the anticoagulant and antiplatelet activity shown in animal work.
Single-agent use: Avoiding other racetams, stimulants and multi-ingredient nootropic blends makes any adverse effect attributable and sidesteps the undeclared-drug combinations found in retail products.

Therapeutic Protocol

Standard clinical protocol: 10 mg twice daily, morning and afternoon, taken after eating, for 1.5 to 3 months, followed by a one-month break before any repeat course. This is the regimen specified by the Russian marketing authorization holder.
Trial-validated regimen: The comparator trial used exactly 20 mg daily as 10 mg twice daily for 56 days (Neznamov & Teleshova 2009). This is the only Noopept schedule with published human efficacy and adverse-effect data attached to it.
Competing approach — self-directed use: Outside Russia, users typically take 10 to 30 mg daily, often sublingually and often cycled two weeks on, one week off. No trial has tested sublingual delivery or any cycling schedule.
Who popularized each approach: The twice-daily clinical schedule comes from the Zakusov Institute’s clinical psychopharmacology laboratory, which developed the compound. The cycled self-directed protocol was popularized through practitioner-facing sites, principally David Tomen’s Nootropics Expert.
Best time of day: Morning and early afternoon. Evening dosing is the most common cause of the reported sleep disturbance, and the activating electroencephalography signature argues against dosing within eight hours of bedtime.
Half-life: Very short. The parent compound is essentially undetectable in plasma within about 25 minutes of an oral dose; elimination is slower in humans than in rabbits or rats, with wide individual variation (Boyko et al. 2004).
Split versus single dose: Split. Because the parent clears within minutes and the active metabolite is what persists, the validated regimen divides the daily amount into two doses rather than one.
Genetic polymorphisms: None are established. Clearance avoids cytochrome P450 enzymes, so catechol-O-methyltransferase, apolipoprotein E4 and folate-pathway variants have no demonstrated bearing on Noopept dosing, and none has been tested.
Sex differences: No human trial reports dosing or response by sex, and no sex-specific dose adjustment has been proposed. The single relevant animal finding concerns early-life exposure rather than adult dosing.
Age: All efficacy data come from participants over 50 or healthy adults aged 20 to 24. For adults at the older end, coexisting hypertension argues for starting at 10 mg once daily rather than the full regimen.
Baseline biomarkers: Response scaled with degree of pre-existing impairment in every trial. A normal score on a validated cognitive test predicts no measurable gain, since no trial has ever demonstrated one in unimpaired adults.
Pre-existing conditions: Cerebrovascular disease, post-concussive syndrome and asthenic syndromes define the populations in which the protocol was validated. Hypertension, hepatic disease and renal disease each contraindicate it rather than modify the dose.

Discontinuation & Cycling

Not a lifelong intervention: The manufacturer specifies discrete courses of 1.5 to 3 months, and no trial reports outcomes past two months. Indefinite daily use sits entirely outside the evidence base and outside the labeled regimen.
Withdrawal effects: None documented. No trial or post-marketing report describes a withdrawal syndrome, rebound cognitive decline or dependence, though absence of reports is weak evidence given how little systematic follow-up exists.
Tapering: Not required by any published protocol. Both trials stopped the drug outright at the end of the course without a taper and reported no discontinuation problem.
Cycling is built into the label: One month off after each course is specified by the manufacturer, though the stated rationale for the interval is not published. Self-directed users commonly cycle more frequently.
Effects fade after stopping: In older working adults, gains persisted for one to two months after the course ended and had returned toward baseline by the third month (Lysenko et al. 2018).

Sourcing and Quality

No legitimate consumer supply exists outside Russia: The only pharmaceutical-grade product is the Russian prescription tablet from JSC LEKKO Pharmaceuticals. Everything sold elsewhere is unregulated research-chemical powder or an illegally marketed supplement.
Compounding is not a route: United States compounding pharmacies may not compound Noopept, because compounding requires an approved active ingredient and Noopept has none. No Western compounder can legally supply it.
No certification program covers it: Because it is not a lawful dietary ingredient, no third-party supplement certifier tests it. The only meaningful check is a batch-specific certificate of analysis from an independent analytical laboratory.
What to look for on a certificate: Identity confirmed by mass spectrometry, assay within 10% of label, and an explicit screen for phenibut, vinpocetine and picamilon, the undeclared drugs found alongside omberacetam in retail testing (Cohen et al. 2021).
Formulation and excipients: The Russian tablet contains lactose, which matters for anyone with lactase deficiency. Bulk powder is lactose-free but carries the weighing problem: 10 mg cannot be measured accurately without a milligram scale.
Storage and stability: Noopept is an ester and is hydrolyzed by moisture. Powder holds only when sealed with desiccant, away from heat and light; doses pre-dissolved for later use degrade.

Practical Considerations

Time to effect: Subjective effects are reported within hours, but every measured cognitive gain in trials required weeks. The comparator trial assessed its outcome at 56 days (Neznamov & Teleshova 2009) and the stroke trial at two months (Amelin et al. 2011).
Common pitfall — expecting a cognitive effect without impairment: Every trial testing cognition enrolled people with measurable deficits, and no study has shown a cognitive gain in unimpaired adults, so the most common error is inferring an effect from an unmeasured baseline.
Common pitfall — evening dosing: Taking the second dose late is the readiest way to convert a modest cognitive gain into disrupted sleep, which for this audience is a net loss on almost any accounting.
Common pitfall — trusting the label: Three-quarters of declared quantities in tested retail products were wrong (Cohen et al. 2021), so assuming the capsule contains 10 mg of what it says is unfounded without an independent assay.
Regulatory status: Noopept is a prescription drug in Russia. In the United States it is neither an approved drug nor a lawful dietary ingredient, it is subject to an import alert, and it is not generally recognized as safe.
Cost and accessibility: Cost is not a barrier — retail product runs roughly $20 for a three-month supply. Legal access is the barrier, and importing it exposes the buyer to seizure and to unverified product quality.
Who funds the evidence: Nearly all efficacy data come from the Zakusov Institute, which developed and patented Noopept and licenses it to its Russian manufacturer. The regulators and medicines-control laboratories cited here gain no revenue from their findings.
Payer incentives: No insurer or national health system outside Russia reimburses Noopept, so no institutional payer has a financial stake in favoring or blocking it. The structural bias here sits with the developer, not with purchasers.

Interaction with Foundational Habits

Sleep: Direct and blunting. Noopept produces the brain-rhythm activation typical of stimulants, and disrupted sleep was one of three adverse effects in its only comparator trial (Neznamov & Teleshova 2009). Practical consequence: no dose after 14:00, and a drop in sleep quality signals a stop rather than a sleep aid.
Nutrition: Direct and modest. The manufacturer specifies dosing after food, which slows absorption of an already poorly absorbed compound but reduces gastric complaints. Alcohol is contraindicated outright. No nutrient depletion is documented, and no specific dietary pattern has been tested alongside it.
Exercise: Potentiating in one narrow setting. Physical work capacity rose under heat exposure in the healthy-volunteer study (Shabanov et al. 2007). No effect on strength, muscle growth or endurance adaptation has been examined, and the blood-pressure signal argues against dosing before heavy resistance work.
Stress management: Direct and potentiating. The active metabolite cycloprolylglycine is reported to modulate the response to anxiety and stress, and asthenic symptoms fell in the neurasthenia trial (Chutko et al. 2008). Practical consequence: it complements rather than replaces stress-management practice, and irritability during a course signals the dose is too high.

Monitoring Protocol & Defining Success

Baseline testing precedes the first dose. It comprises 14 days of home blood-pressure readings, resting heart rate taken on waking, and a validated cognitive screen, so that any later change is measured rather than felt. The baseline blood work covers a complete blood count with platelets, a liver panel, kidney function with creatinine, and fasting glucose with glycated hemoglobin, plus a clotting-time measure where anticoagulants or antiplatelet drugs are already in use. Ongoing monitoring follows a fixed cadence: blood pressure and sleep quality weekly throughout the course, the cognitive screen repeated at 8 weeks, and the full blood panel repeated at the end of the course and again at 6 months where courses are repeated. Success is a measured cognitive gain with blood pressure unchanged and sleep intact; anything less is grounds for stopping.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Home blood pressure, seated	110–125 / 70–80 mmHg	The most consistently reported harm	Two readings averaged after 5 minutes seated; conventional practice acts only above 140/90 mmHg, which is too late here
Resting heart rate	50–70 beats per minute	Detects sympathetic overactivation	Taken on waking before caffeine; conventional laboratories call anything from 60 to 100 beats per minute normal; the weekly trend matters more than any single value
Montreal Cognitive Assessment	≥26 of 30, or a rise over the individual’s own baseline	Turns a felt effect into a measured one	Abbreviated MoCA, a 30-point cognitive screening test; the same time of day each test, since practice effects inflate any retest inside 4 weeks
Complete blood count with platelets	Platelets 175–350 × 10⁹/L	Animal data show antiplatelet activity	No fasting needed; conventional laboratories flag only below 150 × 10⁹/L
International normalized ratio	0.9–1.1 untreated; within the prescribed target if anticoagulated	Detects any additive anticoagulant effect	Abbreviated INR, a standardized measure of clotting time; only informative if anticoagulated or approaching a procedure; morning draw
Alanine aminotransferase and aspartate aminotransferase	10–26 U/L for women and 10–33 U/L for men on the first; 10–26 U/L on the second	Liver disease is a manufacturer contraindication	Abbreviated ALT and AST, liver enzymes released when liver cells are damaged; conventional laboratories flag only above roughly 40 U/L; fasting preferred, and no hard exercise for 48 hours beforehand
Estimated glomerular filtration rate with creatinine	>90 mL/min/1.73 m²	Kidney disease is a manufacturer contraindication	Abbreviated eGFR, a calculated measure of kidney filtering capacity; conventional laboratories flag only below 60 mL/min/1.73 m²; no fasting needed; no creatine supplements or large meat meals for 24 hours beforehand
Fasting glucose and glycated hemoglobin	Glucose 75–86 mg/dL; glycated hemoglobin 4.8–5.3%	Animal work reports gut-hormone and insulin effects, untested in people	Glycated hemoglobin is abbreviated HbA1c and reflects a three-month average of blood sugar; 10–12 hour fast; conventional cut-offs of <100 mg/dL and <5.7% are far looser
Serum brain-derived neurotrophic factor	No established target; track change from the individual’s own baseline	The proposed mechanism marker	Research use only; highly assay-dependent and varies through the day, so a morning draw and a single laboratory

Qualitative markers worth tracking alongside the laboratory values:

Sleep quality and time to fall asleep, recorded nightly
Irritability and emotional reactivity, rated daily by the individual or a household member
Subjective mental clarity and sustained attention during demanding work
Fatigue and exhaustion at the end of a working day
Headache, dizziness or gastrointestinal discomfort, noted with timing relative to each dose

Emerging Research

No registered trial of Noopept exists: A ClinicalTrials.gov search on 2026-09-04 for Noopept, omberacetam and N-phenylacetyl-L-prolylglycine ethyl ester, by both free text and intervention field, returned zero studies. Thirty years after synthesis, no trial has ever been prospectively registered, which is itself the central obstacle to independent evaluation.
Parent compound under registered study: NCT06479629, a Phase 4 randomized placebo-controlled trial of piracetam 800 mg three times daily in 60 adults with diabetic peripheral neuropathy, includes cognitive screening and serum brain-derived neurotrophic factor among its endpoints — the mechanism Noopept is claimed to work through.
Metabolite as the real drug: Work separating the pharmacokinetics of cycloprolylglycine from the parent compound (Boyko et al. 2018) could strengthen the case by identifying a longer-acting active agent, or weaken it by showing the parent contributes little.
Hypoxia-inducible factor 1 as the primary target: If confirmed in people, the finding that Noopept selectively activates this pathway (Vakhitova et al. 2016) would explain the environmental-stress result and give a measurable human endpoint.
Cell-proliferation safety question: Because hypoxia-inducible factor 1 activation is implicated in tumor biology, the finding that Noopept does not stimulate cell proliferation (Zainullina et al. 2019) removes one theoretical concern, though only in cultured cells.
Parkinsonian models: Intranasal Noopept combined with forskolin reversed parkinsonian pathology in genetically modified rats (Dagda et al. 2022). This is the most active line likely to strengthen the case, and it comes from a group with no tie to the developer.
Market surveillance may settle the safety question first: Continued laboratory monitoring of seized and retail product (Vanhee et al. 2025) is the likeliest source of new human harm data, and would weaken rather than strengthen the case for use.
Independent replication remains the decisive gap: No group outside Russia has repeated any efficacy trial. Until a blinded placebo-controlled study runs in unimpaired adults, the cognitive claim cannot move beyond the developer’s own data.

Conclusion

Noopept is a small two-amino-acid molecule, made in Russia in the 1990s, that acts through a substance the brain already produces. In people whose thinking is already impaired by stroke, reduced brain blood flow or head injury, two Russian studies found real improvement on standard memory and mood scores, and a third found less fatigue and anxiety. One study in healthy young adults found better coping with heat, cold and thin air. None of this has been repeated by anyone outside the institute that invented the drug, in every study both patients and researchers knew who was taking it, and no study has ever measured thinking in people whose thinking was unimpaired to begin with.

The recorded harms are modest but point the wrong way for this audience: raised blood pressure, disrupted sleep and irritability, each in a minority of treated patients, and pressure rose far enough in some of them to end their participation. Beyond the drug itself, the product sold outside Russia is frequently mislabeled and sometimes contains other undeclared compounds entirely.

The evidence base is narrow and self-interested. Almost every efficacy finding traces to the institute that holds the patent and licenses the drug to its manufacturer, while the bodies documenting the quality problems have no financial stake either way. That asymmetry, more than any single result, describes where the uncertainty sits.

Top - Benefits - Risks - Protocol

Noopept for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Cognitive Performance in Mild Cognitive Impairment

Medium 🟩 🟩

Reduction of Asthenic and Anxiety Symptoms

Reduced Neurotoxicity of Concurrent Drug Therapy

Tolerance of Heat, Cold and Low-Oxygen Exposure

Low 🟩

Occupational Performance in Older Working Adults

Speculative 🟨

Neurotrophin Induction ⚠️ Conflicted

Amyloid and Tau-Related Neuroprotection

Blood Sugar and Gut-Hormone Effects

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Rise in Blood Pressure

Sleep Disturbance and Irritability

Low 🟥

Adulteration and Inaccurate Dosing of Retail Product

Hypersensitivity Reactions

Speculative 🟨

Headache, Dizziness and Gastrointestinal Discomfort

Increased Bleeding Tendency

Immune Modulation of Uncertain Direction ⚠️ Conflicted

Learning Deficits after Early-Life Exposure

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion